Robeco Institutional Asset Management B.V. Purchases 69,396 Shares of Exelixis, Inc. $EXEL

Robeco Institutional Asset Management B.V. grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 7.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 980,245 shares of the biotechnology company’s stock after buying an additional 69,396 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Exelixis were worth $40,484,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Belpointe Asset Management LLC bought a new position in Exelixis in the first quarter valued at about $572,000. TriaGen Wealth Management LLC purchased a new position in shares of Exelixis in the third quarter valued at about $2,024,000. Fox Run Management L.L.C. bought a new position in Exelixis in the 2nd quarter worth approximately $321,000. Capital Fund Management S.A. grew its stake in Exelixis by 6.6% during the second quarter. Capital Fund Management S.A. now owns 283,639 shares of the biotechnology company’s stock valued at $12,501,000 after acquiring an additional 17,673 shares in the last quarter. Finally, D.A. Davidson & CO. purchased a new stake in shares of Exelixis in the second quarter worth about $212,000. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

NASDAQ EXEL opened at $46.19 on Thursday. Exelixis, Inc. has a twelve month low of $31.90 and a twelve month high of $49.62. The firm’s 50 day moving average price is $42.82 and its two-hundred day moving average price is $41.10. The stock has a market cap of $12.38 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 0.81 and a beta of 0.40.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.47 earnings per share. On average, research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 34,187 shares of Exelixis stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Dana Aftab sold 48,383 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total value of $2,056,277.50. Following the completion of the sale, the executive vice president owned 664,778 shares in the company, valued at $28,253,065. This represents a 6.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 245,235 shares of company stock worth $10,490,600 over the last 90 days. 2.82% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a report on Wednesday, October 8th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Stifel Nicolaus set a $43.00 target price on shares of Exelixis in a research note on Wednesday, November 5th. TD Cowen increased their price target on shares of Exelixis from $44.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Barclays raised their price objective on shares of Exelixis from $40.00 to $41.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.53.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.